|
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
|
Nov 2020
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Risk and timing of cardiovascular death among patients with myelodysplastic syndromes
|
Oct 2017
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure
|
Jul 2020
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse
|
Jul 2020
|
Blood Advances
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients
|
Jun 2019
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide
|
Apr 2020
|
Blood Advances
|
aplastic anemia
|
|
Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia
|
Oct 2019
|
Blood Advances
|
aplastic anemia
|
|
Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years
|
Oct 2019
|
Blood Advances
|
aplastic anemia
|
|
Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes
|
Sep 2017
|
Blood Cancer J
|
myelodysplastic syndromes (MDS)
|
|
Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes.
|
Feb 2017
|
Blood Cancer J
|
myelodysplastic syndromes (MDS)
|
